Purpose: Tissue inhibitors of metalloproteinases (TIMPs) block the catalysis by matrix metalloproteinases (MMPs) and have additional biologic activities, including regulation of cell growth and differentiation, apoptosis, angiogenesis and oncogenesis. We investigated the expression levels of all the four human TIMPs and correlated these levels with those of MMP-9 and vascular endothelial growth factor (VEGF) in proliferative diabetic retinopathy (PDR). Methods: Vitreous samples from 38 PDR and 21 nondiabetic control patients and epiretinal membranes from 14 patients with PDR and 10 patients with proliferative vitreoretinopathy (PVR) were studied by enzyme-linked immunosorbent assay, Western blot analysis and immunohistochemistry. Results: Tissue inhibitor of metalloproteinases-1, TIMP-4, MMP-9 and VEGF levels were significantly higher in vitreous samples from PDR patients than in nondiabetic controls (p < 0.0001 for all comparisons), whereas TIMP-2 and TIMP-3 levels did not differ significantly. TIMP-1, TIMP-4, MMP-9 and VEGF levels in PDR with active neovascularization were significantly higher than those in inactive PDR (p < 0.0001, 0.001, 0.013, 0.004, respectively). Significant positive correlations existed between levels of TIMP-1 and levels of TIMP-4 (r = 0.37; p = 0.004), MMP-9 (r = 0.65; p < 0.0001) and VEGF (r = 0.59; p < 0.0001), between levels of TIMP-4 and levels of MMP-9 (r = 0.61; p < 0.0001) and VEGF (r = 0.62; p < 0.0001) and between levels of MMP-9 and VEGF (r = 0.62; p < 0.0001). TIMP-1 and TIMP-3 were expressed in vascular endothelial cells in PDR epiretinal membranes and in myofibroblasts and leucocytes in PDR and PVR epiretinal membranes. Conclusion: The differential expression of TIMPs in PDR suggests that among the 4 TIMPs, TIMP-1 and TIMP-4 may be possible biomarkers of disease activity.
Introduction
Ischaemia-induced angiogenesis, a process by which new capillaries are formed by sprouting from pre-existing vessels, is the pathological hallmark feature in the ocular microenvironment of patients with PDR. Pathologic neovascularization and outgrowth of fibrovascular tissue at the vitreoretinal interface are major contributors to vision loss due to vitreous haemorrhage and/or traction retinal detachment. The surgically excised fibrovascular membranes from patients with PDR are composed of new blood vessels, asmooth muscle actin (a-SMA)-expressing myofibroblasts and leucocytes expressing the common leucocyte antigen CD45 and the myeloid marker CD11b (Abu ElAsrar et al. 2013a ElAsrar et al. , 2014 ElAsrar et al. , 2015a . In previous studies, we showed the overexpression of angiogenic, inflammatory and fibrogenic factors in the ocular microenvironment of patients with PDR Abu ElAsrar et al. 2013a , 2014 , 2015a Nawaz et al. 2013) . These studies reinforced the paradigm that neovascularization, inflammation and fibrosis are critical mechanisms for PDR development and progression.
The dynamic balance between proangiogenic and antiangiogenic factors is thought to regulate angiogenesis. An upset in the balance in favour of angiogenic factors leads to new vessel formation, whereas the prevalence of antiangiogenic factors shifts the equilibrium to vessel quiescence (Hanahan & Folkman 1996; Carmeliet 2003) . Of the many angiogenic factors produced in the ocular microenvironment of patients with PDR, VEGF plays a pivotal role in promoting retinal neovascularization and vascular leakage (Spranger & Pfeiffer 2001) . Vascular endothelial growth factor (VEGF) exerts its angiogenic effects by binding to its main receptor VEGFR-2 (Shibuya 2006). Hypoxia-inducible factor1a (HIF-1a) accumulates in cells during hypoxia and it heterodimerizes with the constitutively expressed HIF-1b subunit, triggering the activation of many genes encoding proteins that regulate angiogenesis, such as VEGF (Huang et al. 1998; Yamakawa et al. 2003) . However, angiogenesis depends on multiple factors, and when the activity of one angiogenic factor such as VEGF is suppressed, the expression of other angiogenic factors may appear (Dorrell et al. 2007 ). Therapeutic regulation of angiogenesis has emerged as an attractive approach for the treatment of PDR (Salam et al. 2011) . Therefore, restoration of the balance between the angiogenic stimulators and inhibitors by activating endogenous angiogenesis inhibitors can become a potential therapeutic strategy to arrest the progression of PDR angiogenesis. To aid the progress of anti-angiogenic therapies, a more comprehensive understanding of molecules regulating angiogenesis in PDR is of value to identify additional therapeutic targets.
Angiogenesis involves the activation and invasion of endothelial cells through their basement membrane, migration to distal sites, proliferation and tube formation (Deryugina & Quigley 2010) . The growth of new blood vessels requires remodelling, that is breakdown and rebuilding of the extracellular matrix (ECM). Critical enzymes involved in this process are the MMPs (Deryugina & Quigley 2010) . In the ocular microenvironment of patients with PDR, the levels of several MMPs, including MMP-1, MMP-7 and MMP-9 are increased dramatically (Abu El-Asrar et al. 2013a,b) . This upregulation of MMPs is linked to angiogenesis and progression of PDR.
The activity of MMPs is specifically inhibited by TIMPs which bind to the activated forms of MMPs in 1:1 molar stoichiometry in the extracellular space. The human TIMP family consists of four members: TIMP-1, TIMP-2, TIMP-3 and TIMP-4 that are endogenous inhibitors of MMPs and function as negative regulators of the degradation process of the ECM. Tissue inhibitors of metalloproteinases (TIMPs) therefore play a critical role in the maintenance of ECM homoeostasis. Tissue inhibitors of metalloproteinase-1, TIMP-2 and TIMP-4 are secreted in soluble forms, whereas TIMP-3 is associated with ECM. Independently of MMP inhibition, TIMPs also act as signalling multifunctional molecules with cytokine-like activities, thereby regulating various biological processes, including cell growth and differentiation, apoptosis, angiogenesis and oncogenesis. This occurs by direct binding to specific surface receptors to induce signalling and cellular responses (Chirco et al. 2006; Zajgla et al. 2008; Brew & Nagase 2010; Ries 2014; Jackson et al. 2017) . Given the novel roles of TIMPs in angiogenesis, we hypothesized that TIMPs may be involved in the pathogenesis of PDR. Indeed, for the development of alternative and efficient anti-angiogenic therapies, it is necessary to know which TIMPs are more likely to be associated with or involved in the angiogenic process in PDR. Therefore, we determined in a systematic and comparative way the expression levels of all four human TIMPs in the vitreous fluid and epiretinal fibrovascular membranes from patients with PDR and correlated their levels with the levels of the known angiogenic factors VEGF and MMP-9 (Hanahan & Folkman 1996; Carmeliet 2003; Deryugina & Quigley 2010) .
Materials and Methods

Vitreous samples and epiretinal membranes specimens
Undiluted vitreous fluid samples (0.3-0.6 ml) were obtained from 38 patients with PDR during pars plana vitrectomy, for the treatment of tractional retinal detachment and/or nonclearing vitreous haemorrhage. The severity of retinal neovascular activity was graded clinically at the time of vitrectomy using previously published criteria (Aiello et al. 1994) . Neovascularization was considered active if there were visible perfused new vessels on the retina or optic disc present within epiretinal membranes. Neovascularization was considered inactive (involuted) if only nonvascularized, white fibrotic epiretinal membranes were present. Active PDR was present in 19 patients, and inactive PDR was present in 19 patients. We compared the samples from diabetic patients with those of a clinical control cohort. This control group consisted of 21 patients who had undergone vitrectomy for the treatment of rhegmatogenous retinal detachment with no PVR. The interval between symptoms and surgery ranged from 2 to 14 days, with a mean of 6.2 AE 2.8 days. Control subjects were clinically checked to be free from diabetes or other systemic disease. Vitreous samples were collected undiluted by manual suction into a syringe through the aspiration line of vitrectomy, before opening the infusion line. The samples were centrifuged (1500 x g for 10 min, 4°C), and the supernatants were aliquoted and frozen at -80°C until assay. Epiretinal fibrovascular membranes were obtained from 14 patients with PDR during pars plana vitrectomy for the repair of tractional retinal detachment. For comparison, fibrocellular epiretinal membranes were obtained from 10 patients without diabetes undergoing vitreoretinal surgery for the treatment of retinal detachment complicated by PVR. Membranes were fixed for 2 hr in 10% formalin solution and embedded in paraffin.
The study was conducted according to the tenets of the Declaration of Helsinki. All the patients were candidates for vitrectomy as a surgical procedure. All patients signed a preoperative informed written consent and approved the use of the excised epiretinal membranes and vitreous fluid for further analysis and clinical research. The study design and the protocol were approved by the Research Centre and Institutional Review Board of the College of Medicine, King Saud University.
Enzyme-linked immunosorbent assays
Enzyme-linked immunosorbent assay (ELISA) kits for human TIMP-1 (Cat No: DTM100), TIMP-2 (Cat No: DTM200), and VEGF (Cat No: SVE00) were purchased from R&D Systems, Minneapolis, MN, USA. Enzyme-linked immunosorbent assay (ELISA) kits for human TIMP-3 (Cat No: ab119608) and MMP-9 (Cat No: ab100610) were purchased from Abcam, Cambridge, UK. The minimum detection limits for TIMP-1, TIMP-2, TIMP-3, TIMP-4, VEGF and MMP-9 Enzyme-linked immunosorbent assay (ELISA) kits were 80 pg/ ml, 11 pg/ml, 2 pg/ml, 5 pg/ml, 9 pg/ml and 10 pg/ml, respectively. The ELISA plate readings were taken using a Stat Fax-4200 microplate reader from Awareness Technology, Inc., Palm City, FL, USA. The quantification of human TIMP-1, TIMP-2, TIMP-3, TIMP-4, MMP-9 and VEGF in vitreous fluid was determined using ELISA Kits according to the manufacturer's instructions. It is critical to state that in order to determine and compare the levels of specific analytes in solution a volumetric approach was used, because this represents the analyte concentration in the analysed samples. To identify the phenotype of cells expressing TIMP-1 and TIMP-3, sequential double immunohistochemistry was performed. The sections were incubated with the first primary antibodies (anti-CD45 or anti-CD68) and subsequently treated with peroxidiseconjugated secondary antibody to define the leucocytes. The resulting immune complexes were visualized by enzymatic reaction of the 3, 3 0 -diaminobenzidine tetrahydrochloride substrate. Incubation of the second primary antibodies (anti-TIMP-1 or anti-TIMP-3) was followed by treatment with alkaline phosphatase-conjugated secondary antibody and fast red reactions. No counterstain was applied. Omission or substitution of the primary antibody with an irrelevant antibody from the same species and staining with chromogen alone were used as negative controls.
Western blot analysis
For the analysis of the expression of TIMP-1 in the vitreous samples, equal volumes (15 ll) of vitreous samples were boiled in Laemmli's sample buffer (1:1, v/v) under reducing conditions for 10 min. Equal volume of lysis solution was loaded and separated on 12% SDS-PAGE and transferred onto nitrocellulose membranes. Nonspecific binding sites were blocked (1.5 hr, room temperature) with 5% nonfat milk made in Tris-buffered saline containing 0.1%Tween-20 (TBS-T). Blots were then incubated with anti-TIMP-1 antibody (1:1000; ab211926, Abcam) at 4°C overnight. Three TBS-T washings (5 min each) were performed prior to secondary antibody treatment at room temperature for 1 hr. Finally, the immunodetection was performed with the use of Table 1 . Comparisons of mean tissue inhibitors of metalloproteinases (TIMPs), matrix metalloproteinase-9 (MMP-9) and vascular endothelial growth factor (VEGF) levels in proliferative diabetic retinopathy (PDR) patients and nondiabetic patients with rhegmatogenous retinal detachment (RD).
TIMP-1 (ng/ml) 26.8 AE 14.7 47.0 AE 16.1 <0.0001* TIMP-2 (ng/ml) 60.8 AE 36.7 59.9 AE 29.3 0.825 TIMP-3 (ng/ml) 3.5 AE 2.9 4.9 AE 3.5 0.110 TIMP-4 (ng/ml) 0.07 AE 0.12 0.32 AE 0.23 < 0.0001* p-value (Kruskal-Wallis test) <0.0001* <0.0001* MMP-9 (ng/ml) 0.95 AE 0.74 8.9 AE 7.0 <0.0001* VEGF (pg/ml) 12.4 AE 20.9 758.8 AE 876.8 <0.0001* * Statistically significant at 5% level of significance. The data are presented as mean values AE standard deviations in nanograms/ml (ng/ml), except for VEGF levels (picograms/ml, pg/ml). For all tests, the lower detection limits were in the range of pg/ml. 
Results
ELISA levels of TIMPs in vitreous samples from nondiabetic control patients
Human TIMP-1, TIMP-2 and TIMP-3 were detected in all samples, whereas TIMP-4 was detected in only 11 of 21 (52%) samples. Tissue inhibitors of metalloproteinase levels in the samples differed significantly (p < 0.0001; Kruskal-Wallis test). Pairwise comparisons (Mann-Whitney U-test) indicated that TIMP-2 levels were significantly higher than TIMP-1, TIMP-3 and TIMP-4 levels (p = 0.001; p < 0.0001; p < 0.0001, respectively). Tissue inhibitors of metalloproteinase-1 levels were significantly higher than TIMP-3 and TIMP-4 levels (p < 0.0001 for both comparisons). Tissue inhibitors of metalloproteinase-3 levels were significantly higher than TIMP-4 levels (p < 0.0001) ( Table 1) .
ELISA levels of TIMPs in vitreous samples from patients with PDR
All four human TIMPs were detected in all samples. Tissue inhibitors of metalloproteinase levels in samples from PDR patients differed significantly (p < 0.0001; Kruskal-Wallis test). Pairwise comparisons (MannWhitney U-test) indicated that TIMP-2 levels were significantly higher than TIMP-3 and TIMP-4 levels (p < 0.0001 for both comparisons). Fig. 1 . Analysis of all human TIMPs in vitreous samples from nondiabetic control patients and patients with proliferative diabetic retinopathy. Significant positive correlations were detected between levels of tissue inhibitor of metalloproteinase (TIMP)-1 and levels of TIMP-4 (A), matrix metalloproteinase-9 (MMP-9) (B) and vascular endothelial growth factor (VEGF) (C), between levels of TIMP-4 and levels of MMP-9 (D) and VEGF (E) and between levels of MMP-9 and VEGF (F). However, the difference between TIMP-1 and TIMP-2 levels was not statistically significant (p = 0.12). Tissue inhibitors of metalloproteinase-1 levels were significantly higher than TIMP-3 and TIMP-4 levels (p < 0.0001 for both comparisons). Tissue inhibitors of metalloproteinase-3 levels were significantly higher than TIMP-4 levels (p < 0.0001) ( Table 1) .
Comparisons of mean TIMPs, MMP-9 and VEGF levels in vitreous samples from patients with PDR and nondiabetic control patients Mean TIMP-1 and TIMP-4 levels in PDR patients were significantly higher than mean levels in nondiabetic control patients (p < 0.0001 for both comparisons; Mann-Whitney U-test). As a contrast, mean TIMP-2 and TIMP-3 levels did not differ significantly between nondiabetic control patients and PDR patients (p = 0.825; p = 0.11, respectively; Mann-Whitney U-test) ( Table 1) .
In accordance with previous findings (Abu El-Asrar et al. 2013a ) and as a benchmark molecule for validation of the present subject cohorts, MMP-9 was detected in all vitreous samples from patients with PDR and nondiabetic control patients. Mean MMP-9 levels in vitreous samples from PDR patients were significantly higher than the mean levels in nondiabetic control patients (p < 0.0001; Mann-Whitney U-test). VEGF was detected in 13 of 21 (62%) vitreous samples from nondiabetic control patients and in all vitreous samples from patients with PDR. Mean VEGF levels in vitreous samples from PDR patients were significantly higher than mean levels in nondiabetic control patients (p < 0.0001; Mann-Whitney U-test) ( Table 1) .
Relationship between levels of TIMPs, MMP-9 and VEGF and activity of PDR
Comparison of mean levels of TIMP-1, TIMP-2, TIMP-3, TIMP-4, MMP-9 and VEGF among PDR patients with active neovascularization, PDR patients with quiescent disease and nondiabetic control patients was conducted using the Kruskal-Wallis test and the results are shown in Table 2 . The mean levels differed significantly between the three groups for TIMP-1, TIMP-4, MMP-9 and VEGF (p < 0.0001 for all comparisons), but not for TIMP-2 and TIMP-3. Pairwise comparisons (Mann-Whitney U-test) indicated that mean TIMP-1 levels were significantly higher in patients with active PDR than in inactive PDR patients and control patients (p < 0.0001 for both comparisons). In addition, mean TIMP-1 levels in patients with inactive PDR were significantly higher than mean levels in control patients (p = 0.01). Mean TIMP-4 levels were significantly higher in patients with active PDR than in inactive PDR patients and control patients (p = 0.001; p < 0.0001, respectively). In addition, mean TIMP-4 levels in patients with inactive PDR were significantly higher than mean levels in control patients (p = 0.001). For MMP-9 and VEGF, mean levels were significantly higher in patients with active PDR than in patients with inactive PDR (p = 0.013; p = 0.004, respectively) and control patients (p < 0.0001 for both comparisons). In addition, mean MMP-9 and VEGF levels in patients with inactive PDR were significantly higher than mean levels in control patients (p < 0.0001 for both comparisons). 
Correlations
In order to evaluate which specific TIMPs in vitreous samples are associated with the angiogenic process in PDR, we correlated the levels of all human TIMPs with the levels of the angiogenic factors VEGF and MMP-9.Significant positive correlations were found between vitreous fluid levels of TIMP-1 and levels of TIMP-4 (r = 0.37, p = 0.004), MMP-9 (r = 0.65; p < 0.0001) and VEGF (r = 0.59; p < 0.0001). Significant positive correlations were observed between vitreous fluid levels of TIMP-4 and levels of MMP-9 (r = 0.61; p < 0.0001) and VEGF (r = 0.64; p < 0.0001). In addition, the correlation between levels of MMP-9 and levels of VEGF was significant (r = 0.62; p < 0.0001) (Fig. 1) .
Western blot analysis of vitreous samples
With the use of Western blot analysis, we confirmed that TIMP-1 was present in vitreous samples (Fig. 2) . Tissue inhibitors of metalloproteinase-1 migrated at the position of its expected molecular weight and, in accordance with the ELISA measurements of TIMP-1, the immunoreactive signals in samples from PDR patients were on average stronger than those from nondiabetic control subjects.
Immunohistochemical analysis of epiretinal membranes from patients with PDR
No immunostaining was observed in the negative control slides. All membranes showed pathologic new blood vessels that were positive for the endothelial cell marker CD31 (Fig. 3A) . Immunoreactivities for TIMP-1 (Fig. 3B,C,D) and TIMP-3 (Fig. 4A-D) were present in all membranes and were noted in vascular endothelial cells and stromal cells. In addition and in agreement with previous data (Pavloff et al. 1992) , immunoreactivity for TIMP-3 was noted in ECM. In serial sections, the distribution and morphologies of spindle-shaped cells expressing TIMP-1 (Fig. 3B ) and TIMP-3 (Fig. 4A) were similar to those of spindle-shaped stromal cells expressing the myofibroblast marker a-SMA (Fig. 5A ). In addition, double immunohistochemistry demonstrated that stromal cells expressing TIMP-1 and TIMP-3 co-expressed the leucocyte common antigen CD45 (Fig. 5B,C) and the monocyte/macrophage marker CD68 (Fig. 5D,E) .
Immunohistochemical analysis of epiretinal membranes from patients with PVR
No staining was observed in the negative control slides. All membranes contained spindle-shaped myofibroblasts expressing a-SMA (Fig. 6A) . Immunoreactivities for TIMP-1 (Fig. 6B ) and TIMP-3 (Fig. 6C) were noted in spindle-shaped cells. In serial sections, the distribution and morphology of spindle-shaped cells expressing TIMP-1 and TIMP-3 were similar to those of spindle-shaped cells expressing the myofibroblast marker a-SMA (Fig. 6A) . In addition, double immunohistochemistry demonstrated that cells expressing TIMP-1 and TIMP-3 coexpressed CD45 (Fig. 6D,E) .
Discussion
In the present systematic analysis of all four human TIMPs, we showed that TIMP-1 and TIMP-4 were significantly upregulated in the vitreous fluid from patients with PDR. In addition, TIMP-2 and TIMP-3 levels did not differ significantly between PDR patients and nondiabetic control patients.
Previously, we have already demonstrated a positive correlation between the vitreous levels of VEGF and MMP-9 in patients with PDR (Abu El-Asrar et al. 2013a). Here, we corroborated and validated this finding in different patient cohorts and, in addition, used these validated samples for new comparisons of the TIMP analyses. Recently, the roles of all four human TIMPs have been critically evaluated for their functions in tumour biology and it is clear that, contrary to their naming, TIMPs exert many other functions than just MMP inhibition (Jackson et al. 2017) . For instance, TIMP-1 is a welldocumented mitogen that was first identified as erythroid-potentiating activity due to its growth-stimulating effect on erythroid precursors. Tissue inhibitors of metalloproteinase-1 also induces cell proliferation of a variety of cell types that include both normal mesenchymal and epithelial cells, in addition to several tumour cell lines (Chirco et al. 2006; Zajgla et al. 2008; Brew & Nagase 2010; Ries 2014) . There is an emerging concept that TIMP-1 is a multifunctional signalling molecule that may act via its cell surface receptor CD63/integrin b1 complex in addition to exhibiting MMP-inhibiting activity (Kobuch et al. 2015) . These receptors have been shown to be involved in the antiapoptotic role of TIMP-1 via upregulation of focal adhesion kinase, phosphoinositide 3-kinase and extracellular signal-regulated kinase signalling (Chirco et al. 2006; Zajgla et al. 2008; Brew & Nagase 2010; Ries 2014) .
TIMP-1 is overexpressed in many malignancies and is associated with poor prognosis (Ries 2014) . Overexpression of TIMP-1 in cancer cells resulted in enhanced angiogenesis, tumour growth and infiltration (Yoshiji et al. 1998; Bigelow et al. 2009; Cui et al. 2015; Rojiani et al. 2015) . Tissue inhibitor of metalloproteinases-1 overexpression in cancer cells was associated with increased expression of the proangiogenic factor VEGF (Yoshiji et al. 1998) . In the present study, we showed that TIMP-1 was significantly upregulated in the vitreous fluid from patients with PDR. Our subgroup analysis showed that the vitreous levels of TIMP-1 were higher in PDR eyes with active neovascularization compared with the eyes with quiescent disease. In addition, we found significant positive correlations between the vitreous fluid levels of TIMP-1 and those of MMP-9 and the angiogenic biomarker VEGF, a key angiogenic factor in PDR (Spranger & Pfeiffer 2001) . These findings are in accordance with a previous report that demonstrated increased levels of TIMP-1 in the vitreous of PDR patients (Van Geest et al. 2013 ). Using immunohistochemistry, we demonstrated that TIMP-1 was specifically localized in vascular endothelial cells, leucocytes, monocytes/macrophages and myofibroblasts in epiretinal fibrovascular membranes from patients with PDR. Taken together, these findings suggest that upregulation of TIMP-1 in the ocular microenvironment of patients with PDR might contribute to the initiation and progression of angiogenesis associated with PDR. Several studies have documented a proangiogenic role for TIMP-1. This was evidenced by highly vascularized tumours in animals after implantation of TIMP-1 overexpressing cells (Yoshiji et al. 1998; Bigelow et al. 2009; Rojiani et al. 2015) . Tissue inhibitors of metalloproteinase-1 has also been reported to promote VEGF-induced neovascularization in the retina (Yamada et al. 2001) . Endothelial cell tube formation is increased by fibroblast-conditioned media, and TIMP-1 has been identified as the molecular inducer. In addition, recombinant TIMP-1 alone stimulated vessel formation and inhibited the production of tumstatin, an antiangiogenic fragment of collagen IV that is produced by MMP-9 cleavage (Liu et al. 2008) . The role of TIMPs in angiogenesis was investigated in an ex vivo aortic ring model of angiogenesis. Tissue inhibitor of metalloproteinases-2, TIMP-3 and TIMP-4 inhibited angiogenesis, whereas TIMP-1 promoted neovessel growth. The 4 TIMPs stabilized vessels that have already developed, producing a net proangiogenic effect over time (Aplin et al. 2009 ). Tissue inhibitor of metalloproteinases-1 overexpression led to induction of HIF-1a and its downstream target VEGF in cancer cells . It was also demonstrated that overexpression of TIMP-1 in cancer cells led to the upregulation of micro-RNA (miRNA)-210 in a CD63/HIF1a-dependent pathway. miRNA-210 was accumulated in exosomes which displayed proangiogenic properties and promoted tube formation activity in endothelial cells and increased angiogenesis .
In contrast to TIMP-1, several studies provided evidence that TIMP-4 enhances apoptosis and that cancer cell lines overexpressing TIMP-4 showed decreased invasive potential in vitro and decreased tumour growth and microvascular density in vivo (Wang et al. 1997; Lizarraga et al. 2015) . In addition, it was demonstrated that TIMP-4 is an inhibitor of capillary endothelial cell migration, but not of proliferation or of in vivo angiogenesis (Fern andez & Moses 2006) . These findings suggest that TIMP-4 is an important component of the negative control mechanisms of angiogenesis. Unlike other family members, TIMP-4 expression is found to be either absent or present at very low levels in most tissues (Zajgla et al. 2008) . Similarly, in the current study, we detected very low levels of TIMP-4 in the vitreous fluid. Nevertheless, and thanks to an ELISA with a sensitivity in the picogram per millilitre range, we were able to determine that TIMP-4 levels were significantly elevated in the vitreous fluid from patients with PDR, particularly in eyes with active neovascularization. In addition, the levels of TIMP-4 correlated with the levels of the angiogenic factors MMP-9 and VEGF. Our findings suggest that increased levels of TIMP-4 in the vitreous fluid from patients with PDR, particularly active PDR, may reflect a specific regulatory mechanism by the ocular microenvironment of patients with PDR, possibly to counteract the angiogenic activity of TIMP-1. However, it is interesting to note that the mean levels of TIMP-1 in the vitreous samples from PDR patients were about 150-fold higher than those of TIMP-4. The differential expression of TIMP-1 and TIMP-4 might therefore enhance the angiogenic switch and contribute to PDR progression and angiogenesis. In terms of inhibitory catalytic potencies, it is likely that the inhibitory activity of TIMP-1 against MMPs and other metalloproteinases will overshadow that of TIMP-4 in PDR.
In the present study, we demonstrated that TIMP-2 was the most highly expressed TIMP in the vitreous fluid and that TIMP-2 levels did not differ significantly between PDR patients and nondiabetic control patients. Our findings are consistent with previous studies that demonstrated that TIMP-2 is constitutively expressed at high levels in all tissues, whereas the expression of the other three TIMPs demonstrate more selective patterns of tissue distribution and can be induced by a variety of growth factors and cytokines (Chirco et al. 2006; Zajgla et al. 2008; Brew & Nagase 2010; Ries 2014) . Tissue inhibitors of metalloproteinase-2 potently inhibits angiogenic factor-induced endothelial cell proliferation in vitro and angiogenesis in vivo independently of MMP inhibition. These effects require a3b1 integrin-mediated binding of TIMP-2 to endothelial cells (Seo et al. 2003) . In this way, TIMP-2 may inhibit tumour growth and angiogenesis (Guedez et al. 2012 TIMP-3 exhibits antiangiogenic activities via blocking the binding of VEGF to VEGFR-2 and inhibiting proliferation, migration and tube formation of endothelial cells (Qi et al. 2003; Chen et al. 2014; Das et al. 2014) . In addition, TIMP-3 induces apoptosis in several types of cells, such as endothelial cells (Ahonen et al. 2002; Qi & Anand-Apte 2015) . Overexpression of TIMP-3 by vascular endothelial cells effectively inhibited endothelial cell migration and tube formation (Ma et al. 2003) . These properties appeared to be independent of its MMP-inhibitory activity (Ahonen et al. 2002; Qi et al. 2003; Chen et al. 2014; Qi & Anand-Apte 2015) . Tissue inhibitors of metalloproteinase-3 overexpression reduced tumour growth, angiogenesis and inflammation (Ahonen et al. 2002; Chen et al. 2014; Das et al. 2014 ) and TIMP-3 deficiency enhanced tumour growth, angiogenesis, invasion and inflammation (Adissu et al. 2015) . Similarly, deletion of TIMP-3 enhanced diabetic renal injury (Basu et al. 2012 ) and renal injury after unilateral ureteral obstruction (Kassiri et al. 2009; Wang et al. 2014 ) accompanied by enhanced inflammation and interstitial fibrosis. These findings suggest that TIMP-3 is a critical player in regulating the tissue microenvironment, including control of inflammation and fibrosis. In the present study, we detected TIMP-3 at low levels in the vitreous and demonstrated TIMP-3 protein localization in vascular endothelial cells, leucocytes, monocytes/macrophages and myofibroblasts in fibrovascular epiretinal membranes from patients with PDR. It is tempting to speculate that the expression of TIMP-3 in the epiretinal membranes from patients with PDR may be a compensatory counterbalance to limit the extent of tissue degradation, disease progression and angiogenesis.
In the epiretinal membranes from patients with PDR and PVR, inflammatory and fibrotic changes are characterized by the presence of inflammatory cells and a-SMA-expressing myofibroblasts in the stromal compartment (Abu El-Asrar et al. 2008 , 2013a , 2014 , 2015b . Myofibroblasts, the key cellular mediators of fibrosis, are contractile cells, characterized by the expression of a-SMA and their presence is a marker of progressive fibrosis (Wynn 2008) . Using immunohistochemistry, we demonstrated that TIMP-1 and TIMP-3 proteins were localized in myofibroblasts, leucocytes and monocytes/macrophages in both PDR and PVR epiretinal membranes. These immunohistochemical data are in agreement with previous studies demonstrating that TIMP-1 and TIMP-3 are upregulated in fibrotic disorders (Kikuchi et al. 1997; Nie et al. 2004; Garcia-Alvarez et al. 2006; Sa et al. 2015) and that TIMP-1 and TIMP3 are localized in fibroblasts and myofibroblasts in fibrotic diseases (Kikuchi et al. 1997; Selman et al. 2000; Nie et al. 2004; Garcia-Alvarez et al. 2006; Sa et al. 2015) . Tissue inhibitors of metalloproteinase-1 stimulates proliferation and migration of fibroblasts and induces the cells to secrete transforming growth factor b1and collagen type 1. In addition, TIMP-1 significantly increases a-SMA levels and transformation of fibroblasts into myofibroblasts (Selman et al. 2000) . In the present study, we demonstrated that a-SMA-expressing myofibroblasts co-expressed TIMP-1and TIMP-3 in epiretinal membranes, thus supporting a role for TIMP-1 and TIMP-3 in regulating the differentiation of myofibroblasts in vivo.
In conclusion, the systematic analysis and comparison of all four human TIMPs yielded the insight of clear differential expression of TIMPs in PDR. The increase of TIMP-1 and TIMP-4 levels in the vitreous fluid from patients with PDR, particularly in eyes with active neovascularization and their significant correlation with the levels of the angiogenic biomarkers MMP-9 and VEGF, suggests that TIMP-1 and TIMP-4 may be possible biomarkers of disease activity. Expanding our knowledge of how TIMPs are involved in PDR pathophysiology may be useful in identifying new therapeutic interventions aimed at modulating activities of MMPs and TIMPs.
